FORM 4

Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549
-------------	------------

	STATEMENT OF CHANGES IN BENEFICIAL	<b>OWNERSHIP</b>
to Section 16. Form 4 or Form 5		
obligations may continue. See		

OMB APPR	OVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HAASER CHARLES B  (Last) (First) (Middle)						Issuer Name and Ticker or Trading Symbol     YIELD10 BIOSCIENCE, INC. [ YTEN ]      Just of Earliest Transaction (Month/Day/Year)									ationship of Reporting k all applicable) Director Officer (give title below)		ŭ	10% O Other ( below)	wner
C/O YIELD10 BIOSCIENCE, INC. 19 PRESIDENTIAL WAY					09/01/2021									VP Fin and CAO					
(Street) WOBUR	RN MA		)1801		4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indi Line) X	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
(City)	(St	ate) (Z	Zip)																
		Table	I - Noi	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or E	Benefi	cially	/ Own	ed			
Dat			2. Transad Date (Month/Da	Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (AD Disposed Of (D) (Instr. 3, 5)			, 4 and Sec Ber Ow		Amount of curities neficially ned Following ported		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or Pri	ce	Transa	action(s) 3 and 4)			(111341. 4)
Common Stock 09.				09/01/	/2021				F		286(1)	I	\$	6.71	4	,439		D	
Common Stock													4,	I,002 <sup>(2)</sup>		I	By 401(k) Plan		
		Tal									osed of, onvertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		of		6. Date Exerci Expiration Dat (Month/Day/Ye		te	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amour or Number of Shares	er					

## **Explanation of Responses:**

- $1. \ Represents \ shares \ withheld \ in \ payment \ of \ withholding \ taxes \ upon \ partial \ vesting \ of \ RSUs \ granted \ 3/1/2021.$
- 2. Shares acquired as Company matching contributions under the Yield10 Bioscience, Inc. 401(k) Plan.

/s/ Megan N. Gates, attorney-

in-fact

\*\* Signature of Reporting Person Date

09/03/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.